By David Tuller, DrPH This post is about a serious issue–ethical approval for research studies involving children. It is also about how powerful institutions, like leading medical journals, respond to concerns. But the story is really too long and complicated. I recommend it only for those following things pretty closely or who for whatever reason …
Trial By Error: The School Absence Study, Revisited Read More »
By David Tuller, DrPH I wanted to post something this week, but not a whole long thing. So I thought I’d just post the top of what I’ll post in full next week. This week ends the first half–six months!–of my crowdfunded project. Sometime soon I’ll post something or other looking backward and forward a …
Trial By Error: A Sneak Preview of Next Week’s Post Read More »
By David Tuller, DrPH As it turns out, the University of Bristol did complain about me to Berkeley. I found out recently that there has indeed been “private and confidential communication” at a “senior level,” as Sue Paterson, Bristol’s director of legal services, suggested in her thuggish letter to me last month. I haven’t seen …
By David Tuller, DrPH On September 20, 2017, a BMJ Publishing Group journal, Archives of Disease in Childhood published the SMILE trial. This trial investigated an intervention called the Lightning Process as a treatment for kids with CFS/ME (as the study called the disease). The lead investigator was Professor Esther Crawley, the University of Bristol …
Trial By Error: My Questions for the Science Media Centre Read More »
By David Tuller, DrPH So let’s talk about Professor Esther Crawley’s SMILE trial, published in September by the journal Archives of Disease in Childhood, one of the BMJ Publishing Group’s titles. The study reported that a commercial intervention called the Lightning Process was an effective treatment for children with CFS/ME when offered along with what …
Trial By Error: The SMILE Trial’s Undisclosed Outcome-Swapping Read More »
A dengue virus vaccine was recently developed not only to prevent first infections, but to avoid severe disease that may occur upon second and third infections. This consequence, called antibody dependent enhancement (ADE), now appears to be caused by the vaccine itself.
